Increase of hepatitis B surface antigen loss rate in hepatitis B e antigen positive chronic hepatitis B patients treated with nucleos (t) ide analogs and pegylated interferon alfa-2a sequential therapy
10.3760/cma.j.issn.1000-6680.2011.10.013
- VernacularTitle:核苷(酸)类似物序贯干扰素治疗乙型肝炎病毒e抗原阳性慢性乙型肝炎患者的临床观察
- Author:
Zhongwen WU
;
Yimin ZHANG
;
Jifang SHENG
;
Lanjuan LI
- Publication Type:Journal Article
- Keywords:
Hepatitis B,chronic;
Nucleos(t)ide analogs;
Peg IFNα-2a;
HBsAg
- From:
Chinese Journal of Infectious Diseases
2011;29(10):611-614
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the changes of hepatitis B sarfaceantigen (HBsAg) titer in hepatitis B e antigen (HBeAg) positive chronic hepatitis B (CHB) patients treated with nucleos(t)ide analogs and pegylated interferon alfa-2a (PEG IFNα-2a) sequential therapy.Methods Among 6 HBeAg positive CHB patients,3 patients were treated with nucleos(t)ide analogs followed by PEG IFNα-2a for 48 weeks,3 patients were treated with nucleos(t)ide analog monotherapy.The serum HBsAg,anti-HBs,HBeAg,anti-HBe andanti-HBcweredetectedusingthetime-resolved immunofluorometric assay and serum hepatitis B virus (HBV) DNA levels were determined by Taqman polymerase chain reaction (PCR) every 12 weeks.Results HBsAg loss were achieved in three patients after 48-week nucleos(t)ide analogs and PEG IFNα-2a sequential therapy.However,the HBsAg titers of another 3 patients varied from 100 IU/mL to 320 IU/mL.ConclusionIn HBeAg positive CHB patients who obtain virologic response accompanied with HBsAg titer decreasing dramatically by nucleos(t) ide analog treatment,PEG IFNα-2a sequential treatment can increase HBsAg clearance rate.
